Predictive Oncology EBITDA 2010-2025 | POAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Predictive Oncology ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Predictive Oncology ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$46B
Hims & Hers Health (HIMS)	$12.4B
Doximity (DOCS)	$10.9B
Tempus AI (TEM)	$10B
IRhythm Technologies (IRTC)	$5.2B
Hinge Health (HNGE)	$3.8B
Inspire Medical Systems (INSP)	$2.6B
Privia Health (PRVA)	$2.4B
10x Genomics (TXG)	$1.6B
Phreesia (PHR)	$1.6B
Enovis (ENOV)	$1.5B
Clover Health Investments (CLOV)	$1.5B
Schrodinger (SDGR)	$1.4B
Omnicell (OMCL)	$1.4B
Azenta (AZTA)	$1.2B
Evolent Health (EVH)	$1.1B
Claritev (CTEV)	$650M
Fulgent Genetics (FLGT)	$636M
Veradigm (MDRX)	$514M
Standard BioTools (LAB)	$494M
Talkspace (TALK)	$380M
Zepp Health (ZEPP)	$349M
Butterfly Network (BFLY)	$336M
Carlsmed (CARL)	$325M
TruBridge (TBRG)	$314M
Health Catalyst (HCAT)	$266M
Nyxoah SA (NYXH)	$254M
Outset Medical (OM)	$250M
SOPHiA GENETICS SA (SOPH)	$228M
CapsoVision (CV)	$192M